Inipharm Initiates Dosing in Phase 1 Study of Its Small Molecule Inhibitor of HSD17B13

BELLEVUE, Wash. & SAN DIEGO–(BUSINESS WIRE)–Inipharm, a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, today announced that it has begun dosing in a Phase 1 study of INI-822, its orally-delivered small molecule inhibitor of HSD17B13. INI-822, believed to be the first small molecule inhibitor of HSD17B13 to advance to clinical development, is under development for fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH). “Mul
Click here to view original post